A UK woman with beta thalassaemia is cured after receiving the NHS’s first gene-editing therapy, Casgevy, in Nov. 2025.

Kavita Mehta, a woman from southern England diagnosed with beta thalassaemia at one month old, is hopeful she may be cured after receiving the NHS’s first gene-editing therapy, Casgevy, in November 2025. The CRISPR-based treatment reactivated her body’s fetal hemoglobin production, allowing her to stop regular blood transfusions. After chemotherapy and a six-week hospital stay, she is recovering at home, reporting improved energy and well-being. Doctors believe the therapy is working, and if she remains transfusion-free for a year, she will be considered cured. Mehta, who works in hospitality, hopes the treatment will enable greater freedom, including travel and a normal life, and she advocates for broader access to the therapy.